Peptide-based inhibitors targeting the PD-1/PD-L1 axis: potential immunotherapeutics for cancer

Bojko, Magdalena; Węgrzyn, Katarzyna; Sikorska, Emilia; Ciura, Piotr; Battin, Claire; Steinberger, Peter; Magiera-Mularz, Katarzyna; Dubin, Grzegorz; Kulesza, Adam; Sieradzan, Adam K.; Spodzieja, Marta; Rodziewicz-Motowidło, Sylwia

doi:10.1016/j.tranon.2024.101892

Translational Oncology

2024

DOI: 10.1016/j.tranon.2024.101892

|View full text |Cite

Peptide-based inhibitors targeting the PD-1/PD-L1 axis: potential immunotherapeutics for cancer

Magdalena Bojko,

Katarzyna Węgrzyn,

Emilia Sikorska

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1). 7–13 However, successful inhibitor candidates have yet to progress through clinical trials to the market.…”

mentioning

confidence: 99%

Light-activated azobenzene peptide inhibitor of the PD-1/PD-L1 interaction

Hayward,

Goddard,

Cominetti

et al. 2024

Chem. Commun.

View full text Add to dashboard Cite

show abstract

“…1). 7–13 However, successful inhibitor candidates have yet to progress through clinical trials to the market.…”

mentioning

confidence: 99%

Light-activated azobenzene peptide inhibitor of the PD-1/PD-L1 interaction

Hayward,

Goddard,

Cominetti

et al. 2024

Chem. Commun.

View full text Add to dashboard Cite

show abstract

Editorial: Co-inhibitory immune checkpoint proteins as biomarkers and therapeutic targets in cancer

Nunes-Xavier

2024

Translational Oncology

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Peptide-based inhibitors targeting the PD-1/PD-L1 axis: potential immunotherapeutics for cancer

Cited by 2 publications

References 70 publications

Light-activated azobenzene peptide inhibitor of the PD-1/PD-L1 interaction

Light-activated azobenzene peptide inhibitor of the PD-1/PD-L1 interaction

Editorial: Co-inhibitory immune checkpoint proteins as biomarkers and therapeutic targets in cancer

Contact Info

Product

Resources

About